drugset
drugset / Trial / NCT02261077

Pharmacokinetics, Safety and Tolerability of Rising Doses of Buscopan® in Healthy Male Volunteers

NCT02261077 ↗

Phase 1 Completed 60 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to investigate pharmacokinetics, safety and tolerability of Buscopan® after single rising dose and after multiple rising doses

Timeline

Start
2007-05
Primary completion
2007-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Hyoscine butylbromide Unknown 20 mg Oral
Subject Hyoscine butylbromide Unknown 60 mg Oral
Subject Hyoscine butylbromide Unknown 100 mg Oral
Subject Hyoscine butylbromide Unknown 200 mg Oral
Subject Hyoscine butylbromide Unknown 400 mg Oral

Indications

No indication recorded.